Who is managing your bone health, oncologist or endocrinologist?

Posted by Zebra @californiazebra, 4 days ago

I’m a breast cancer patient on Letrozole for 5.5 years so far and 10 year goal. 2 years ago I had osteopenia and my oncologist wanted to put me on Zometa, but said ask your endocrinologist. My endocrinologist said no, he would do Prolia first and only when I have osteoporosis because Medicare won’t cover for osteopenia. So I haven’t been on anything. I’m reading that Medicare will cover those drugs for AI drug induced osteopenia (true?) and that oncologists choose Zometa for breast cancer as protection from cancer spreading to bones (true?). I feel like the two specialists need to talk so I get the appropriate treatment. Oncologist just told me to have my endocrinologist order DEXA that is due and manage my bone health. Endocrinologist says he can order but it won’t be covered since he has no history on that for me. I feel like a ping pong ball so I’m wondering who is managing bone health for other breast cancer/AI patients. Thanks for any input.

Interested in more discussions like this? Go to the Breast Cancer Support Group.

Profile picture for marceen @marceen

@californiazebra
Exactly!!!!! As one get's older there is a feeling that the patient is sluffed off - they are going to die soon anyway. Pretty cynical but these days a lot of their profits go to the insurance process and the staff in my endo doc's office is larger than the actual doctors......I can understand that.

There is a web site that you can see how much your doc makes - the extra stuff like lectures on a cruise, or dinners, or other stuff from the big pharma reps. These are the women clunking down the hallway with the sample suitcase.......you can search by name. By accident, I typed in the wrong city and some plastic surgeon's name popped up in so cal. Well, just by these additional functions he was getting 100,000 dollars a year.

The stuff "behind the curtain"...................There is a parathyroid surgery center in southern calif that is good too. I went to Forida and had a Harvard "and" Yale surgeon to take out the tiny parathyroid.....they were so so good and sent me a file with pictures (normal parathyroid is the size of a pea - mine was an inch wide).........anyway, I sent them two award winning wines from Oregon.....nice to be nice on both ends.....

Jump to this post

@marceen
My doctors are aging right along with me. I think doctors, like every other profession, start to burn out over time. Some just want to scale back to easy by the book cases. The trick is to build a medical team that likes a challenge. 😊

REPLY
Profile picture for Zebra @californiazebra

@mistymar
I take 2000 IU D3 so the 100 K2 would likely be sufficient. Thanks for your reply.

Jump to this post

@californiazebrI
I take 2,000 of D3 also............and my potassium is also a combo gummy with magnesium.
Number 1 on my list - always is the PTH blood test..........otherwise calcium is sucked up and out in the blood.

REPLY
Profile picture for marceen @marceen

@californiazebrI
I take 2,000 of D3 also............and my potassium is also a combo gummy with magnesium.
Number 1 on my list - always is the PTH blood test..........otherwise calcium is sucked up and out in the blood.

Jump to this post

@marceen
I’ll look into that. I have quite an array of medical conditions so I’m already overwhelmed by the onslaught of appointments and research. I’ll add that to my list to look into before my DEXA follow-ups though. I try to squeeze in a little fun here and there between medical stuff. 🥰

REPLY

Hey there!
My rheumatologist with a cc to my oncologist manages my bone health .

REPLY
Profile picture for kensiejames @kensiejames

Hey there!
My rheumatologist with a cc to my oncologist manages my bone health .

Jump to this post

@kensiejames
Good to know. Thanks for your reply.

REPLY

Hey there!
Medicare will cover test ordered by your oncologist. At this point your bone health is at risk from the cancer so there should be no issue with approval from Medicare .
“Zometa can help reduce the risk of early-stage breast cancer returning or spreading to the bones. It changes the bone environment to make it harder for stray cancer cells to survive and grow there, particularly in postmenopausal women or premenopausal women whose ovaries are suppressed”.
All the best🙏🏻

REPLY
Profile picture for kensiejames @kensiejames

Hey there!
Medicare will cover test ordered by your oncologist. At this point your bone health is at risk from the cancer so there should be no issue with approval from Medicare .
“Zometa can help reduce the risk of early-stage breast cancer returning or spreading to the bones. It changes the bone environment to make it harder for stray cancer cells to survive and grow there, particularly in postmenopausal women or premenopausal women whose ovaries are suppressed”.
All the best🙏🏻

Jump to this post

@kensiejames I appreciate your post about the benefits of Zometa for early-stage breast cancer. Even though that's not a ton of information, it's more information than any of my doctors have offered! So far, when pressed by me as to whether the Zometa is primarily for bone health (preventing fractures) or to offer protection against possible cancer spreading to the bones, they have emphasized that it's to prevent fracture more than to prevent cancer spread. Had I declined Zometa, though, perhaps they would have emphasized the cancer spread prevention.

Your information prompted me to look a bit further. Google AI's main statement echoes your statement. There is mention of Zometa altering the bone microenvironment which makes the growth of cancer cells less likely.

Google AI also states that ideally one would start it within 3 months after surgery, which I did not do. But it also goes on to add "However, studies indicate that it does not improve survival rates more than 2 years of treatment compared to longer durations." The sources for this statement are the National Cancer Institute and breastcancer.org. The statement is somewhat vague and one would need to track down the original studies to really understand their findings.

These same sources are referred to behind this:
The long-term implications of using Zometa (zoledronic acid) in breast cancer patients include a reduced risk of breast cancer recurrence in the bone and improved survival rates among postmenopausal women. However, there are potential side effects, such as osteonecrosis of the jaw and kidney toxicity, that patients should be aware of.

REPLY
Profile picture for kensiejames @kensiejames

Hey there!
Medicare will cover test ordered by your oncologist. At this point your bone health is at risk from the cancer so there should be no issue with approval from Medicare .
“Zometa can help reduce the risk of early-stage breast cancer returning or spreading to the bones. It changes the bone environment to make it harder for stray cancer cells to survive and grow there, particularly in postmenopausal women or premenopausal women whose ovaries are suppressed”.
All the best🙏🏻

Jump to this post

@kensiejames
Thank you for your response.

REPLY
Profile picture for prarysky @prarysky

@kensiejames I appreciate your post about the benefits of Zometa for early-stage breast cancer. Even though that's not a ton of information, it's more information than any of my doctors have offered! So far, when pressed by me as to whether the Zometa is primarily for bone health (preventing fractures) or to offer protection against possible cancer spreading to the bones, they have emphasized that it's to prevent fracture more than to prevent cancer spread. Had I declined Zometa, though, perhaps they would have emphasized the cancer spread prevention.

Your information prompted me to look a bit further. Google AI's main statement echoes your statement. There is mention of Zometa altering the bone microenvironment which makes the growth of cancer cells less likely.

Google AI also states that ideally one would start it within 3 months after surgery, which I did not do. But it also goes on to add "However, studies indicate that it does not improve survival rates more than 2 years of treatment compared to longer durations." The sources for this statement are the National Cancer Institute and breastcancer.org. The statement is somewhat vague and one would need to track down the original studies to really understand their findings.

These same sources are referred to behind this:
The long-term implications of using Zometa (zoledronic acid) in breast cancer patients include a reduced risk of breast cancer recurrence in the bone and improved survival rates among postmenopausal women. However, there are potential side effects, such as osteonecrosis of the jaw and kidney toxicity, that patients should be aware of.

Jump to this post

@prarysky
Good info. Thank you for your response. Meds always sound like a miracle until you get to that fine print with the scary side effects. Jaw osteonecrosis is pretty darn scary! I’ll wait for my upcoming DEXA results and go from there.

REPLY
Please sign in or register to post a reply.